\documentclass[10pt]{article}

\usepackage{fullpage}
\usepackage{setspace}
\usepackage{parskip}
\usepackage{titlesec}
\usepackage[section]{placeins}
\usepackage{xcolor}
\usepackage{breakcites}
\usepackage{lineno}
\usepackage{hyphenat}





\PassOptionsToPackage{hyphens}{url}
\usepackage[colorlinks = true,
            linkcolor = blue,
            urlcolor  = blue,
            citecolor = blue,
            anchorcolor = blue]{hyperref}
\usepackage{etoolbox}
\makeatletter
\patchcmd\@combinedblfloats{\box\@outputbox}{\unvbox\@outputbox}{}{%
  \errmessage{\noexpand\@combinedblfloats could not be patched}%
}%
\makeatother


\usepackage{natbib}




\renewenvironment{abstract}
  {{\bfseries\noindent{\abstractname}\par\nobreak}\footnotesize}
  {\bigskip}

\titlespacing{\section}{0pt}{*3}{*1}
\titlespacing{\subsection}{0pt}{*2}{*0.5}
\titlespacing{\subsubsection}{0pt}{*1.5}{0pt}


\usepackage{authblk}


\usepackage{graphicx}
\usepackage[space]{grffile}
\usepackage{latexsym}
\usepackage{textcomp}
\usepackage{longtable}
\usepackage{tabulary}
\usepackage{booktabs,array,multirow}
\usepackage{amsfonts,amsmath,amssymb}
\providecommand\citet{\cite}
\providecommand\citep{\cite}
\providecommand\citealt{\cite}
% You can conditionalize code for latexml or normal latex using this.
\newif\iflatexml\latexmlfalse
\providecommand{\tightlist}{\setlength{\itemsep}{0pt}\setlength{\parskip}{0pt}}%

\AtBeginDocument{\DeclareGraphicsExtensions{.pdf,.PDF,.eps,.EPS,.png,.PNG,.tif,.TIF,.jpg,.JPG,.jpeg,.JPEG}}

\usepackage[utf8]{inputenc}
\usepackage[greek,ngerman,english]{babel}



\usepackage{float}








\begin{document}

\title{Synthesis of A Novel PET Probe for the Glycogen Synthase Kinase-3
(GSK-3) Imaging}



\author[1]{SRSTT Radiopharmaconnect}%
\affil[1]{Radiopharmaconnect}%


\vspace{-1em}



  
  \date{April 26, 2024}


\begingroup
\let\center\flushleft
\let\endcenter\endflushleft
\maketitle
\endgroup








\sloppy


\textbf{}\selectlanguage{english}
\begin{figure}[H]
\begin{center}
\includegraphics[width=0.70\columnwidth]{figures/CAFACHEM/CAFACHEM}

\end{center}
\end{figure}

\textbf{\href{https://www.srsweb.org/cafachem2020}{\textbf{\textbf{CAFACHEM~2020}}}
\textbf{}} organizers are grateful for the support
of~\textbf{\href{https://www.pmod.com/web/}{\textbf{\textbf{\textbf{PMOD}}}}}

\par\null\selectlanguage{english}
\begin{figure}[H]
\begin{center}
\includegraphics[width=0.70\columnwidth]{figures/pmod/pmod}

\end{center}
\end{figure}

\textbf{Authors:~~Heather M Berg}, Nicholas R. Nelson, Aditya Bansal,
Val J. Lowe, Timothy R. DeGrado, Mukesh K Pandey

Mayo Clinic Department of Radiology

\par\null

\textbf{\textbf{Background}}

Glycogen Synthase Kinase-3 (GSK-3) is a regulatory enzyme which has been
implicated in various cancers, Alzheimer's disease, diabetes, bipolar
disorder, and depression\textsuperscript{1}. A non-invasive imaging of
GSK-3 and understanding its role in disease pathology would be
instrumental in disease diagnosis, staging and in therapeutic
advancement\textsuperscript{1}.

\par\null

\textbf{\textbf{Aims}}

The objective is to synthesize and radiolabel ligands for the GSK-3 as a
positron emission tomography (PET) probe. Secondary aim was to measure
the in vitro binding affinity of the developed PET probe towards GSK-3\selectlanguage{greek}α
\selectlanguage{english}and GSK-3\selectlanguage{greek}β \selectlanguage{english}kinases.

\par\null

\textbf{Methods}

Multi- steps organic synthesis has been carried out for the synthesis of
precursor and reference compound. Radio fluorination was carried out
using cryptand. The labelling was performed at 150\selectlanguage{ngerman}°C for 30 minutes in
DMSO using 18-crown-6 as a catalyst. Final product was purified using
semi preparative HPLC.

\par\null\selectlanguage{english}
\begin{figure}[H]
\begin{center}
\includegraphics[width=0.70\columnwidth]{figures/Screenshot-2020-08-01-at-16-11-50/Screenshot-2020-08-01-at-16-11-50}
\caption{{{[}\textsuperscript{18}F{]}CNBI
{\label{822676}}%
}}
\end{center}
\end{figure}

\par\null

\textbf{Results and Conclusion}

~Radiolabelling was achieved in \textasciitilde{}20-25 \% yield decay
corrected to end of synthesis after purification.~Intermediates,
precursor and reference compound were fully characterized by
\textsuperscript{1}H-NMR, \textsuperscript{19}F-NMR,
\textsuperscript{13}C-NMR and HRMS. In vitro binding study showed
IC\textsubscript{50} value of 29.1\selectlanguage{ngerman}±1.6 nM and 29.7±5.8 nM towards GSK-3\selectlanguage{greek}α
\selectlanguage{english}and GSK-3\selectlanguage{greek}α β, \selectlanguage{english}respectively.~\textbf{}

\par\null

\textbf{References}

\textbf{1.} M K. Pandey, T. R. DeGrado. Glycogen Synthase Kinase -3
(GSK-3) Targeted Therapy and Imaging. Theranostics, 2016:6(4):571-593.

\textbf{2.} G. Luo, L. Chen, C. R. Burton, H. Xiao, P. Sivaprakasam et.
al. Discovery of Isonicotinamides as Highly Selective, Brain Penetrable,
and Orally Active Glycogen Synthase Kinase-3 Inhibitors. J Med Chem.
2016:59(3):1041-1051.

\par\null\selectlanguage{english}
\begin{figure}[H]
\begin{center}
\includegraphics[width=0.70\columnwidth]{figures/Screenshot-2020-07-10-at-12-20-47/Screenshot-2020-07-10-at-12-20-47}

\end{center}
\end{figure}

\selectlanguage{english}
\FloatBarrier
\end{document}

